首页> 外文期刊>European journal of clinical pharmacology >Paracetamol for intravenous use in medium--and intensive care patients: pharmacokinetics and tolerance.
【24h】

Paracetamol for intravenous use in medium--and intensive care patients: pharmacokinetics and tolerance.

机译:中重症监护患者静脉使用扑热息痛:药代动力学和耐受性。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: We studied the pharmacokinetics of paracetamol and determine the incidence of hypotension after intravenous administration in medium- (MCU) and intensive care (ICU) patients. METHODS: All patients on the ICU/MCU starting with paracetamol i.v. were included, yielding 38 patients. Blood samples were collected at predetermined time points to determine paracetamol serum concentration. The number of patients with a clinically relevant reduction in systolic blood pressure (SBP) and the number of patients that needed intervention to regain an acceptable blood pressure level were assessed. RESULTS: Overall, pharmacokinetic data were roughly comparable with earlier publications, but differences were noted in the subgroup ICU patients. Also, there was a trend to a larger peak serum concentration (p = 0.052) and a significantly smaller volume of distribution (p = 0.033) in MCU patients compared with ICU patients. Twenty-two percent (22%) and 33% of patients had a clinically relevant reduction in systolic blood pressure (SBP) 15 and 30 min after start of paracetamol infusion, respectively. In six patients (16%), an intervention was needed to correct blood pressure. Overall, SBP was significantly reduced at T = 15 min and 30 min postinfusion (p < 0.003 at both time points) when compared with SBP at the start of paracetamol infusion. CONCLUSIONS: Further research on differences in paracetamol pharmacokinetics between ICU and MCU patients is warranted, as these differences might result in differences in efficacy. Furthermore, administration of paracetamol i.v. as potential cause of hypotension in the critically ill patient must not be overlooked.
机译:目的:我们研究了对乙酰氨基酚的药代动力学,并确定中(MCU)和重症监护(ICU)患者静脉内给药后低血压的发生率。方法:所有在ICU / MCU上的患者均从对乙酰氨基酚静脉注射开始。其中包括38例患者。在预定的时间点采集血样以确定扑热息痛的血清浓度。评估了具有临床意义的收缩压降低(SBP)的患者人数以及需要干预以恢复可接受的血压水平的患者人数。结果:总体而言,药代动力学数据与早期出版物大致相当,但在ICU亚组患者中发现差异。而且,与ICU患者相比,MCU患者的血清峰值浓度较高(p = 0.052),分布体积明显较小(p = 0.033)。开始扑热息痛输注后15分钟和30分钟,分别有22%(22%)和33%的患者收缩压(SBP)有临床意义的降低。在六名患者(16%)中,需要采取干预措施来纠正血压。总体而言,与扑热息痛开始输注时的SBP相比,输注后T = 15分钟和30分钟时SBP显着降低(两个时间点的p <0.003)。结论:有必要进一步研究ICU和MCU患者之间对乙酰氨基酚药代动力学的差异,因为这些差异可能会导致疗效差异。此外,对乙酰氨基酚静脉内给药。因为绝不能忽视重症患者低血压的潜在原因。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号